Investigation Report on Chinese Ossotide Market, 2018-2022
- China Research and Intelligence Co., Ltd. (CRI)
- August 2018
- 30 pages
According to statistics, the incidence of rheumatoid arthritis in China is 0.2% to 0.36%, and the number of patients is up to 5 to 10 million. Like rheumatoid arthritis, osteoarthritis is one of the most common arthritis and a manifestation of articular degeneration with age. At the end of 2017, the number of people aged 60 and above reached 241 million in China, accounting for 17.3% of the total population. Some research has pointed out that over 60% of Chinese people aged 60 and above are suffering from osteoarthritis as the population is ageing. Typical symptoms of osteoarthritis are joint pains, joint deformities, and joint dysfunction, decreasing patients' mobility and quality of life.
Ossotide can regulate bone metabolism and stimulate the proliferation of bone cells to foster the formation of new bones. It can also regulate calcium and phosphorus metabolism and increase bone calcium deposition to prevent osteoporosis. Ossotide was originally developed by Nanjing Xinbai Pharmaceutical Co., Ltd. There are many Ossotide manufacturers in China. The top 5 market players are Harbin Medisan Pharmaceutical Co., Ltd., Heilongjiang ZBD Pharmaceutical Co., Ltd., Heilongjiang Jiangshi Pharmaceutical Co., Ltd., Nanjing Xinbai Pharmaceutical Co., Ltd. and Anhui Hongye Pharmaceutical Co., Ltd. In 2017, their market share by sales revenue reached over 90%. Harbin Medisan Pharmaceutical Co., Ltd. captured the biggest market share by sales value about 35%.
According to CRI, after Ossotide was launched in China, the sales value of Ossotide kept growing before 2012 and fluctuated from 2013 to 2017. Overall, the annual sales value in China increased from less than CNY 120 million in 2007 to CNY 363 million in 2017. The Chinese Ossotide market will continue to grow in the coming years.
- Development environment of Ossotide
- Sales of Ossotide in China
- Competition pattern of Chinese Ossotide Market
- Major Ossotide manufacturers in China
- Prices of Ossotide in China
- Prospect of the Chinese Ossotide market from 2018 to 2022
Have query on this report?Make an Enquiry
Table of Content
1 RELEVANT CONCEPTS OF OSSOTIDE
1.1 Indications for Ossotide
1.2 Development History of Ossotide in China
1.3 Patents and Government Approval on Ossotide in China
2 SALES OF OSSOTIDE IN CHINA, 2013-2017
2.1 Sales Value of Ossotide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Ossotide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Ossotide by Dosage Form in China, 2013-2017
3 MAJOR OSSOTIDE MANUFACTURERS IN CHINA, 2013-2017
3.1 Analysis on Market Share of Major Ossotide Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Harbin Medisan Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.3 Heilongjiang ZBD Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.4 Heilongjiang Jiangshi Pharmaceutical Co., Ltd.
3.5 Nanjing Xinbai Pharmaceutical Co., Ltd.
3.6 Anhui Hongye Pharmaceutical Co., Ltd.
4 PRICES OF DIFFERENT MANUFACTURERS' OSSOTIDE IN CHINA, 2017-2018
4.1 Harbin Medisan Pharmaceutical Co., Ltd. (Maijinli)
4.2 Heilongjiang ZBD Pharmaceutical Co., Ltd.
4.3 Heilongjiang Jiangshi Pharmaceutical Co., Ltd. (Gujie)
4.4 Nanjing Xinbai Pharmaceutical Co., Ltd. (Guzheng)
4.5 Anhui Hongye Pharmaceutical Co., Ltd. (Shundaxin)
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017